$825m looks like a lot to spend acquiring a drug that only sold €72m ($79m) in 2023, but sales of Sanofi’s Enjaymo are forecast to grow fast, and Recordati SpA has pounced on it. The asset is the only approved therapy for the rare B-cell lymphoproliferative disorder cold agglutinin disease (CAD), and faces little competition in the near term.
Key Takeaways
- Recordati has bought Sanofi’s cold agglutinin disease therapy Enjaymo for $825m.
- The drug will be Recordati’s second-biggest seller in 2030, according to Evaluate Pharma’s forecasts
Only around 11,000 patients in Europe, the US and Japan have CAD, but Recordati says it expects Enjaymo (sutimlimab), which was approved in these markets in 2022, to generate revenue in excess of €150m in 2025, with peak sales potential of €250-€300m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
